Can umbilical cord stem cells reverse frailty in the elderly?

NCT ID NCT07705464

Not yet recruiting Disease control Sponsor: Miracle Biomedical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-stage trial tests the safety of an experimental stem cell product called MiraMSC in people aged 60 to 85 with mild to moderate frailty. MiraMSC is made from donated umbilical cord stem cells and is given through an IV. The study will look at different dose schedules to see if the treatment is well tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MiraMSC-FS-001, a product made from donated umbilical cord stem cells (mesenchymal stem cells), given by IV infusion
What this could lead to: If safe and effective, this approach could point toward a treatment that reduces frailty and improves physical function in older adults.
What could go wrong: This is a very early, small Phase 1 trial focused only on safety, not on proving the treatment works. The stem cells may not improve frailty, and there could be unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAILTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAILTY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.